Donald L. Rosenstein, M.D.

Professor and Director, Comprehensive Cancer Support Program



Rosenstein, Donald 2010


Office: Physicians Office Building, Room 3134

Phone: (919) 843-8895




B.A., Wesleyan University
M.D., Northwestern University School of Medicine
Residency in Adult Psychiatry, Yale University


Summary Statement:

Dr. Rosenstein is Director of the UNC Comprehensive Cancer Support Program with joint appointments in the Departments of Psychiatry and Medicine. He also serves as Vice-Chair for the Division of Hospital Psychiatry and is the Training Director for the UNC Fellowship in Psychosomatic Medicine. The Comprehensive Cancer Support Program provides UNC oncology patients with a wide range of educational, medical, psychiatric and psycho-social services. The clinical, teaching and research aspects of this program operate at both the North Carolina Cancer Hospital and Carolina Pointe II. Dr. Rosenstein came to UNC from the National Institutes of Health (NIH) where he was Clinical Director of the National Institute of Mental Health (NIMH) and the Chief of the Psychiatry Consultation-Liaison Service. Dr. Rosenstein also served as Vice-Chair of the NIH Medical Executive Committee and for many years chaired both the Clinical Center Ethics Committee and the NIMH Institutional Review Board. He is currently President of the Academy of Psychosomatic Medicine.


Representative Publications:

  1. “Depression and end-of-life care for patients with cancer,” Rosenstein DL, Dialogues in Clinical
    Neuroscience 48, 13(1): 101-8, 2011. PMID: 21485750
    “Depression and end-of-life care for patients with cancer,” Rosenstein DL, Dialogues in ClinicalNeuroscience 48, 13(1): 101-8, 2011. PMID: 21485750
  2. “Single fatherhood due to cancer,” Yopp JM and Rosenstein DL. Psychooncology, 2011
  3. “Survivorship care planning after the Institute of Medicine recommendations: How are we faring?,” Stricker CT, Jacobs LA, Risendal B, Jones A, Panzer S, Ganz PA, Syrjala K, McCabe M, Baker KS, Miller K, Casillas J, Rosenstein D, Campbell M, and Palmer SC. J Cancer Surviv Dec 2011;5(4):358-70
  4. “HIV/HCV Co-infected Virologic Responders To Pegylated IFN and Ribavirin Therapy More Frequently Incur IFN-Related Adverse Events than Non-responders”, Osinusi A, Rasimas JJ, Bishop R, Proschan M, McLaughlin M, Murphy A, Cortez KJ, Polis MA, Masur H, Rosenstein DL, Kottilil S, JAIDS, 53(3): 357-63, 2010 PMID: 20101190
  5. “Bipolar Mania and Capacity to Consent: Recommendations for Investigators and IRBs,” Misra S, Rosenstein DL, Socherman R, and Gonzini L. in: IRB, Ethics & Human Research, 32: 7-15, 2010.